The estimated Net Worth of Ye Liu is at least $57.5 million dollars as of 11 January 2024. Ye Liu owns over 1,910,500 units of EyePoint Pharmaceuticals Inc stock worth over $823,817 and over the last few years Ye sold EYPT stock worth over $56,669,231.
Ye has made over 3 trades of the EyePoint Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Ye sold 1,910,500 units of EYPT stock worth $37,159,225 on 11 January 2024.
The largest trade Ye's ever made was selling 1,910,500 units of EyePoint Pharmaceuticals Inc stock on 11 January 2024 worth over $37,159,225. On average, Ye trades about 970,167 units every 75 days since 2023. As of 11 January 2024 Ye still owns at least 100,221 units of EyePoint Pharmaceuticals Inc stock.
You can see the complete history of Ye Liu stock trades at the bottom of the page.
Ye's mailing address filed with the SEC is 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI, , 200041.
Over the last 7 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B... et Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include: